U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C62H88N13O14P.C2H3O2.Co
Molecular Weight 1388.3918
Optical Activity UNSPECIFIED
Defined Stereocenters 13 / 14
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROXOCOBALAMIN ACETATE

SMILES

[Co+3].CC([O-])=O.C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)C2[N-]C1=C(C)C3=NC(=CC4=NC(=C(C)C5=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]5CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)C(C)(C)[C@@H]3CCC(N)=O)OP([O-])(=O)O[C@@H]6[C@@H](CO)O[C@@H]([C@@H]6O)N7C=NC8=C7C=C(C)C(C)=C8

InChI

InChIKey=KPFAAKYTRSSOQN-UVKKECPRSA-K
InChI=1S/C62H90N13O14P.C2H4O2.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;1-2(3)4;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);1H3,(H,3,4);/q;;+3/p-3/t31-,34-,35-,36-,37+,41-,52-,53-,56?,57+,59-,60+,61+,62+;;/m1../s1

HIDE SMILES / InChI

Molecular Formula C2H3O2
Molecular Weight 59.044
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Co
Molecular Weight 58.933195
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C62H88N13O14P
Molecular Weight 1270.4146
Charge -2
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 13 / 14
E/Z Centers 0
Optical Activity UNSPECIFIED

Acetic acid (a component of vinagre) is used in medicine for the treatment of otitis externa caused by bacterial infections. The solution containing acetic acid was approved by FDA.

CNS Activity

Curator's Comment: Acetic acid was shown to cross the blood brain barrier in rats.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CYANOKIT

Approved Use

Cyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. (1.1) If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. (1.2) The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. (1.2) 1.1 Indication Cyanokit is indicated for the treatment of known or suspected cyanide poisoning. 1.2 Identifying Patients with Cyanide Poisoning Cyanide poisoning may result from inhalation, ingestion, or dermal exposure to various cyanide-containing compounds, including smoke from closed-space fires. Sources of cyanide poisoning include hydrogen cyanide and its salts, cyanogenic plants, aliphatic nitriles, and prolonged exposure to sodium nitroprusside. The presence and extent of cyanide poisoning are often initially unknown. There is no widely available, rapid, confirmatory cyanide blood test. Treatment decisions must be made on the basis of clinical history and signs and symptoms of cyanide intoxication. If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. Table 1 Common Signs and Symptoms of Cyanide Poisoning Symptoms Signs Headache Altered Mental Status (e.g., confusion,disorientation) Confusion Seizures or Coma Dyspnea Mydriasis Chest tightness Tachypnea / Hyperpnea (early) Nausea Bradypnea / Apnea (late) Hypertension (early) / Hypotension (late) Cardiovascular collapse Vomiting Plasma lactate concentration ≥ 8 mmol/L In some settings, panic symptoms including tachypnea and vomiting may mimic early cyanide poisoning signs. The presence of altered mental status (e.g., confusion and disorientation) and/or mydriasis is suggestive of true cyanide poisoning although these signs can occur with other toxic exposures as well. The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. Smoke Inhalation Not all smoke inhalation victims will have cyanide poisoning and may present with burns, trauma, and exposure to other toxic substances making a diagnosis of cyanide poisoning particularly difficult. Prior to administration of Cyanokit, smoke-inhalation victims should be assessed for the following: Exposure to fire or smoke in an enclosed area Presence of soot around the mouth, nose or oropharynx Altered mental status Although hypotension is highly suggestive of cyanide poisoning, it is only present in a small percentage of cyanide-poisoned smoke inhalation victims. Also indicative of cyanide poisoning is a plasma lactate concentration ≥ 10 mmol/L (a value higher than that typically listed in the table of signs and symptoms of isolated cyanide poisoning because carbon monoxide associated with smoke inhalation also contributes to lactic acidemia). If cyanide poisoning is suspected, treatment should not be delayed to obtain a plasma lactate concentration. 1.3 Use with Other Cyanide Antidotes Caution should be exercised when administering other cyanide antidotes simultaneously with Cyanokit, as the safety of co-administration has not been established. If a decision is made to administer another cyanide antidote with Cyanokit, these drugs should not be administered concurrently in the same intravenous line. [see Dosage and Administration (2.3)

Launch Date

2006
Curative
VOSOL

Approved Use

For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial.

Launch Date

1960
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4511.6 μM × h
5 g single, intravenous
dose: 5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
HYDROXOCOBALAMIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
26.2 h
5 g single, intravenous
dose: 5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
HYDROXOCOBALAMIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day multiple, intramuscular
Dose: 20 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 13 years
Health Status: unhealthy
Age Group: 13 years
Sex: M
Sources:
20 g single, intravenous
Highest studied dose
Dose: 20 g
Route: intravenous
Route: single
Dose: 20 g
Sources:
unhealthy, 26.9 years
Health Status: unhealthy
Age Group: 26.9 years
Sex: M
Sources:
5 g single, intravenous
Overdose
Dose: 5 g
Route: intravenous
Route: single
Dose: 5 g
Sources:
unhealthy, 3 years
Health Status: unhealthy
Age Group: 3 years
Sex: F
Sources:
5 g single, intravenous
Dose: 5 g
Route: intravenous
Route: single
Dose: 5 g
Sources:
unhealthy, 62 years
Health Status: unhealthy
Age Group: 62 years
Sex: M
Sources:
2000 ug 2 times / day multiple, oral
Dose: 2000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 2000 ug, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim

Drug as victim

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Direct exposure to ammonia and hyperammonemia increase the extracellular accumulation and degradation of astroglia-derived glutathione in the rat prefrontal cortex.
2010-09
Effects of ammonia and allopurinol on rat hippocampal NMDA receptors.
2010-03
AMP deaminase and adenosine deaminase activities in liver and brain regions in acute ammonia intoxication and subacute toxic hepatitis.
2010-01-22
Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with aliphatic and aromatic carboxylates.
2009-04-01
Effects of acute ammonia toxicity on nitric oxide (NO), citrulline-NO cycle enzymes, arginase and related metabolites in different regions of rat brain.
2005-10
Utilization of geraniol is dependent on molybdenum in Pseudomonas aeruginosa: evidence for different metabolic routes for oxidation of geraniol and citronellol.
2005-07
[Antioxidant enzymes of the rat liver, brain, heart and erythrocytes in ammonia intoxication].
2005-06-11
Acute ammonia intoxication induces an NMDA receptor-mediated increase in poly(ADP-ribose) polymerase level and NAD metabolism in nuclei of rat brain cells.
2004-06
Sources of oxygen radicals in brain in acute ammonia intoxication in vivo.
2003-08-15
Cobalamin transport proteins and their cell-surface receptors.
2003-06-13
Ammonia-induced heme oxygenase-1 expression in cultured rat astrocytes and rat brain in vivo.
2002-12
Production of ethanol and xylitol from corn cobs by yeasts.
2001-03
Evaluation of a novel vitamin E coated cellulosic membrane hollow fiber dialyzer.
2001-02-24
Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring.
2001-02
Exploring infection of wheat and carbohydrate metabolism in Mycosphaerella graminicola transformants with differentially regulated green fluorescent protein expression.
2001-02
Di-tert-butyl phosphate complexes of cobalt(II) and zinc(II) as precursors for ceramic M(PO3)2 and M2P2O7 materials: synthesis, spectral characterization, structural studies, and role of auxiliary ligands.
2001-01-29
Modelling the influence of pH and organic acid types on thermal inactivation of Bacillus cereus spores.
2001-01-22
Identification of lactic acid bacteria constituting the predominating microflora in an acid-fermented condiment (tempoyak) popular in Malaysia.
2001-01-22
Control of electrochemical reactions at the capillary electrophoresis outlet/electrospray emitter electrode under CE/ESI-MS through the application of redox buffers.
2001-01-15
[DOTA-bis(amide)]lanthanide complexes: NMR evidence for differences in water-molecule exchange rates for coordination isomers.
2001-01-05
Optimised determination of clobazam in human plasma with extraction and high-performance liquid chromatography analysis.
2001-01-05
[Acetyl starch as volume substitute, a possible alternative to HES].
2001-01-05
Clostridium hungatei sp. nov., a mesophilic, N2-fixing cellulolytic bacterium isolated from soil.
2001-01
Long-term stability characterization of a controlled release gastrointestinal therapeutic system coated with a cellulose acetate pseudolatex.
2001-01
A survey of lipolytic and glycolytic end-products in commercial Cheddar enzyme-modified cheese.
2001-01
Cation-exchange purification of mutagenized bovine beta-casein expressed in transgenic mouse milk: its putative Asn68-linked glycan is heterogeneous.
2001-01
In vitro mixed ruminal microorganism fermentation of whole cottonseed coated with gelatinized corn starch and urea.
2001-01
Teprenone promotes the healing of acetic acid-induced chronic gastric ulcers in rats by inhibiting neutrophil infiltration and lipid peroxidation in ulcerated gastric tissues.
2001-01
Effect of ruminal vs postruminal administration of degradable protein on utilization of low-quality forage by beef steers.
2001-01
Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography.
2001-01
Measurement of myocardial blood flow with PET using 1-11C-acetate.
2001-01
Subcellular localization of Rab17 by cryo-immunogold electron microscopy in epithelial cells grown on polycarbonate filters.
2001
Evaluation of copper availability to plants in copper-contaminated vineyard soils.
2001
Conversion of 4-hydroxyacetophenone into 4-phenyl acetate by a flavin adenine dinucleotide-containing Baeyer-Villiger-type monooxygenase.
2000-12
Characterization of two novel propachlor degradation pathways in two species of soil bacteria.
1999-02
Carbon-arsenic bond cleavage by a newly isolated gram-negative bacterium, strain ASV2.
1995-03
Cloning and sequencing of the gene which encodes the highly inducible acetamidase of Mycobacterium smegmatis.
1993-03
Location and sequence of the todF gene encoding 2-hydroxy-6-oxohepta-2,4-dienoate hydrolase in Pseudomonas putida F1.
1991-07-31
Purification and characterization of aryl acylamidase from Nocardia globerula.
1991-07-01
Enzymes of vitamin B6 degradation. Purification and properties of 5-pyridoxic-acid oxygenase from Arthrobacter sp.
1986-11-15
Bacterial organomercurial lyase: overproduction, isolation, and characterization.
1986-11-04
Enzymes of vitamin B6 degradation. Purification and properties of two N-acetylamidohydrolases.
1985-02-25
Disruption of the blood-brain barrier in hyperammonemic coma and the pharmacologic effects of dexamethasone and difluoromethyl ornithine.
1985
Prevention of methionine and ammonia-induced coma by intravenous infusion of a branched chain amino acid solution to rats with liver injury.
1984-10
Modification of drug action by hyperammonemia.
1984-04
Metabolism of resorcinylic compounds by bacteria. Purification and properties of acetylpyruvate hydrolase from Pseudomonas putida 01.
1975-05-25
Microbiological degradation of diazepam.
1975
The degradation of paracetamol (4-hydroxyacetanilide) and other substituted acetanilides by a Penicillium species.
1975
Purification and characterization of the nocardial acetylesterase involved in 2-butanone degradation.
1974-12
The utilization of acetate for synthesis in Escherichia coli.
1954-03
Patents

Sample Use Guides

Cyanokit (hydroxocobalamin for injection): one 5 g vial is a complete starting dose
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment: Hydroxocobalamin (OH-Cbl), when used to treat vitamin B12 deficiency, is better retained by the body than is cyanocobalamin (CN-Cbl), but the availability to cells has not been studied systematically. In a series of experiments, were compared the uptake and internalization of OH-Cbl and CN-Cbl bound to transcobalamin II (TCII) by a human cell model, the HeLa cell. TCII-OH-Cbl was: (1) taken up in larger amounts per unit time, (2) the greater uptake was not a consequence of more effective attachment to receptors of TCII-Cbl nor to a more rapid regeneration of receptors, (3) the difference was expressed during the phase of internalization of TCII-Cbl, (4) with CN-Cbl, the stages of binding to receptors plus internalization were more readily reversed, and (5) larger amounts of OH-Cbl were internalized and converted to active coenzyme forms of Cbl.
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:38:07 GMT 2025
Edited
by admin
on Mon Mar 31 21:38:07 GMT 2025
Record UNII
S535M27N3Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROXOCOBALAMIN ACETATE
EP   MART.   USP-RS   VANDF   WHO-DD  
Common Name English
ACETATOCOBALAMIN [MI]
Preferred Name English
HYDROXOCOBALAMIN ACETATE [EP MONOGRAPH]
Common Name English
HYDROXOCOBALAMIN ACETATE [JAN]
Common Name English
HYDROXOCOBALAMIN ACETATE [VANDF]
Common Name English
HYDROXOCOBALAMIN ACETATE [MART.]
Common Name English
HYDROXOCOBALAMIN ACETATE [USP-RS]
Common Name English
Hydroxocobalamin acetate [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C26017
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C77156
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY
DRUG BANK
DBSALT001895
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY
DAILYMED
S535M27N3Q
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY
PUBCHEM
131634603
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY
DRUG CENTRAL
4644
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY
EVMPD
SUB02579MIG
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY
CAS
214142-68-4
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
NON-SPECIFIC SUBSTITUTION
ECHA (EC/EINECS)
245-019-7
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY
FDA UNII
S535M27N3Q
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY
RXCUI
236302
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY RxNorm
ChEMBL
CHEMBL2103737
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY
CAS
22465-48-1
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY
EPA CompTox
DTXSID8046901
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY
SMS_ID
100000089042
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY
MERCK INDEX
m6116
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY Merck Index
RS_ITEM_NUM
1324308
Created by admin on Mon Mar 31 21:38:07 GMT 2025 , Edited by admin on Mon Mar 31 21:38:07 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY